Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 2, 2011, Pages 416-422

  Iyú, David ^a   Glenn, Jackie R ^a   White, Ann E ^a   Fox, Sue C ^a   Heptinstall, Stan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

adenosine; antiplatelet drugs; arterial thrombosis; blood cells; cell physiology; g proteins; hemostasis; P2Y 12 antagonists; platelet receptor blockers; platelets; thrombosis

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; CANGRELOR; DIPYRIDAMOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PURINE SYNTHESIS; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; VENOUS BLOOD;

ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; BLOOD PLATELETS; CELL ADHESION MOLECULES; ERYTHROCYTES; HUMANS; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RECEPTORS, THROMBIN; THIOPHENES;

EID: 79551496648     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219501     Document Type: Article

References (40)

1. 2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
2. 12 receptor in platelet activation. J Clin Invest. 2004;113:340-344.
3. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nu-cleotide receptor signaling in platelets. J Thromb Haemost. 2006;4: 2317-2326.
4. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemostasis. 2008;99:466-472.
5. 12 antagonists as inhibitors of platelet function. Thromb Haemostasis. 2010;105 [Epub ahead of print].
6. 12 blockers. J Thromb Haemost. 2009;7:262-265.
7. 12 receptor antagonist pharmacoki-netics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemostasis. 2010;103:535-544.
8. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9:154-169.
9. Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res. 1989;65:531-537.
10. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg's Arch Pharmacol. 2000;362:299-309.
11. Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood-important roles for leukocytes and eryth-rocytes. J Thromb Haemost. 2005;3:2331-2339.
12. Cooper JA, Hill SJ, Alexander SPH, Rubin PC, Horn EH. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryp-tamine release in human platelets. Br J Clin Pharmacol. 1995;40:43-50.
13. Amisten S, Braun OO, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res. 2008;122:47-57.
14. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor regulating platelet function. J Throm Haemost. 2010;8:817-827.
15. Kitakaze M, Hori M, Sato H, Takashima S, Inoue M, Kitabatake A, Kamada T. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res. 1991;69:1402-1408.
16. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, Saffer LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR. The endothelial cells Ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 1997;99:1351-1360.
17. Marcus AJ, Broekman MJ, Drosopoulos JHF, Pinsky DJ, Islam N, Gayle RB III, Maliszewski CR. Thromboregulation by endothelial cells: significance for occlusive vascular disesases. Arterioscler Throm Vasc Biol. 2001;21:178-182.
18. Koszalka P, Ozüyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, Gear A, Weber AA, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Godecke A, Schrader J. Targeted disruption of cd73/ecto-5'-nucelotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95:814-821.
19. Marcus AJ, Broekman MJ, Drosopoulos JHF, Olson KE, Islam N, Pinsky D, Levi R. Role of CD39 (NTPDase-1) in thromboregulation, cerebro-protection and cardioprotection. Semin Thromb Hemost. 2005;31: 234-246.
20. Glenn JR, White AE, Johnson AJ, Fox SC, Myers B, Heptinstall S. Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced aggregation via rapid hydrolysis. Platelets. 2008;19: 59-69.
21. 1. Cell Calcium. 2004;35:39-46.
22. 12 receptor by adenosine diphosphate potentiates the antiplatelet effects of prostacyclin. J Thromb Haemost. 2007;5:577-582.
23. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta. 1996;1286:153-181.
24. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol. 2007;27:1004-1013.
25. Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol. 1983;93:21-26.
26. Dawicki DD, Agarwal KC, Parks RE. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol. 1985;34: 3965-3972.
27. Gamboa A, Abraham R, Diedrich A, Shibao C, Paranjape SY, Farley G, Biaggioni I. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke. 2005;36:2170-2175.
28. Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease and the vasculature. Vasc Pharmacol. 2008;48:143-149.
29. Bjorkman JA, Kirk I, van Giezen JJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation. 2007;116(suppl):II-28 [Abstract 245].
30. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J, Walter U. cAMP-and cGMP-protein kinase phosphorylation sites of the focal adhesion vasodilator- stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem. 1994;269:14509-14517.
31. 2 on human platelet function. Platelets. 2010;21(5):329-342.
32. Glenn JR, Heptinstall S. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium. Thromb Haemostasis. 1998;80:321-325.
33. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. Coordinated adenine nucleotide phosphohy-drolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A(2B) receptors. J Exp Med. 2003;198: 783-796.
34. Ledoux L, Runembert I, Koumanov K, Michel JB, Trugnan G, Fried-lander G. Hypoxia enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: role of membrane lipids. Circ Res. 2003; 92:848-855.
35. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of endothelial equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005;202:1493-1505.
36. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol. 2001;134:253-258.
37. Willmot M, Zhao L, Heptinstall S, Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis. 2004;13:138-140.
38. Zhao L, Fletcher S, Weaver C, Leonardi-Bee J, May J, Fox S, Willmot M, Heptinstall S, Bath O. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemostasis. 2005;93:527-534.
39. Sprigg N, Gray LJ, England T, Willmot MR, Zhao L, Sare GM, Bath PM. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS One. 2008;3:e2852.
40. Bath PM, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, Diener HC, Estol C, Roberts R; PRoFESS Study Group. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010;41:732-738.